Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment
- 15 April 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (7) , 987-993
- https://doi.org/10.1097/01.tp.0000057244.03192.bd
Abstract
Background. Previous studies have suggested an increased risk of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (EBV-PTLD) in patients receiving tacrolimus for immunosuppression. We hypothesized that after correction for confounding variables, immunosuppression with tacrolimus is not associated with an increased risk of EBV-PTLD. Methods. Potential cases of EBV-PTLD, identified by chart review, were independently ascertained by three clinicians and defined using published criteria. Agreement in diagnosing EBV-PTLD was measured using Kappa coefficients. Unadjusted and adjusted relative risk estimates were determined using proportional hazards regression. Results. Twenty-three cases of EBV-PTLD were identified in 221 patients, a proportion of 10.4% (95% confidence interval [CI]: 6.4%–14.4%). Multivariable analysis revealed that immunosuppression with tacrolimus was associated with an increased risk of EBV-PTLD (relative risk 3.10: 95% CI: 1.21–7.92), as was age at transplantation as a continuous variable (parameter estimate −0.15, P =0.03). Kappa coefficients in diagnosing EBV-PTLD and subclassifying as neoplastic and non-neoplastic EBV-PTLD were 0.73 (95% CI: 0.54–0.93) and 0.54 (95% CI: 0.40–0.68), respectively. Patients with neoplastic PTLD demonstrated a lower probability of survival than patients with non-neoplastic PTLD and non-cases. Conclusions. Immunosuppression with tacrolimus and young age at transplantation are associated with an increased risk of EBV-PTLD in children undergoing liver transplantation, although we cannot exclude detection bias as an explanation for this observed increase. Good agreement between observers can be achieved using previously published criteria for defining EBV-PTLD. Patients with neoplastic EBV-PTLD may have a worse prognosis, and thus identification of risk factors for the development of this subtype of the disorder may be more important.Keywords
This publication has 12 references indexed in Scilit:
- Post‐transplant Lymphoproliferative Syndrome in the Pediatric Liver Transplant PopulationAmerican Journal of Transplantation, 2001
- RISK OF LYMPHOID NEOPLASIA AFTER CARDIOTHORACIC TRANSPLANTATIONTransplantation, 2000
- EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERSTransplantation, 1999
- LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATION IN CHILDRENTransplantation, 1999
- Early Signs And Risk Factors For The Increased Incidence Of Epstein-Barr Virus-Related Posttransplant Lymphoproliferative Diseases In Pediatric Liver Transplant Recipients Treated With TacrolimusTransplantation, 1997
- POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER TRANSPLANTATIONTransplantation, 1996
- AN INCREASED INCIDENCE OF EPSTEIN-BARR VIRUS INFECTION AND LYMPHOPROLIFERATIVE DISORDER IN YOUNG CHILDREN ON FK506 AFTER LIVER TRANSPLANTATION1Transplantation, 1995
- TacrolimusDrugs, 1993
- Description of an In Situ Hybridization Methodology for Detection of Epstein-Barr Virus RNA in Paraffin-Embedded Tissues, with a Survey of Normal and Neoplastic TissuesDiagnostic Molecular Pathology, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990